cd2 antibody (NSJ Bioreagents)
NSJ Bioreagents is a verified supplier 
NSJ Bioreagents manufactures this product 
99
Structured Review
NSJ Bioreagents
cd2 antibody
Cd2 Antibody, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 416 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd2+antibody/CD2+Antibody/custom%40v8198%4042589488
Average 99 stars, based on 416 article reviews
Cd2 Antibody, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 416 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd2+antibody/CD2+Antibody/custom%40v8198%4042589488
Average 99 stars, based on 416 article reviews
cd2 antibody - by Bioz Stars,
2026-09
99/100 stars
Images
Related Articles
Flow Cytometry:Article Title: Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors. Article Snippet: ildtype or CD2-KO CD4+ T cells was analyzed. Successful knockout of CD2 was demonstrated by flow cytometry through staining with a 1:200 dilution of an allophycocyanin (APC)-labeled anti-CD2 antibody (RPA-2.10 clone, BioLegend) for 30 min on ice. Wildtype (untreated), CD2-KO or mock-treated primary CD4+ T cells were incubated with 10 µg/ml of the chimeric CD2 Ab or an isotype control for 60 min on FACS:Article Title: Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors. Article Snippet: ildtype or CD2-KO CD4+ T cells was analyzed. Successful knockout of CD2 was demonstrated by flow cytometry through staining with a 1:200 dilution of an allophycocyanin (APC)-labeled anti-CD2 antibody (RPA-2.10 clone, BioLegend) for 30 min on ice. Wildtype (untreated), CD2-KO or mock-treated primary CD4+ T cells were incubated with 10 µg/ml of the chimeric CD2 Ab or an isotype control for 60 min on Cytometry:Article Title: Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors. Article Snippet: ildtype or CD2-KO CD4+ T cells was analyzed. Successful knockout of CD2 was demonstrated by flow cytometry through staining with a 1:200 dilution of an allophycocyanin (APC)-labeled anti-CD2 antibody (RPA-2.10 clone, BioLegend) for 30 min on ice. Wildtype (untreated), CD2-KO or mock-treated primary CD4+ T cells were incubated with 10 µg/ml of the chimeric CD2 Ab or an isotype control for 60 min on Blocking Assay:Article Title: Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors. Article Snippet: ildtype or CD2-KO CD4+ T cells was analyzed. Successful knockout of CD2 was demonstrated by flow cytometry through staining with a 1:200 dilution of an allophycocyanin (APC)-labeled anti-CD2 antibody (RPA-2.10 clone, BioLegend) for 30 min on ice. Wildtype (untreated), CD2-KO or mock-treated primary CD4+ T cells were incubated with 10 µg/ml of the chimeric CD2 Ab or an isotype control for 60 min on Staining:Article Title: Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors. Article Snippet: ildtype or CD2-KO CD4+ T cells was analyzed. Successful knockout of CD2 was demonstrated by flow cytometry through staining with a 1:200 dilution of an allophycocyanin (APC)-labeled anti-CD2 antibody (RPA-2.10 clone, BioLegend) for 30 min on ice. Wildtype (untreated), CD2-KO or mock-treated primary CD4+ T cells were incubated with 10 µg/ml of the chimeric CD2 Ab or an isotype control for 60 min on Marker:Article Title: Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors. Article Snippet: ildtype or CD2-KO CD4+ T cells was analyzed. Successful knockout of CD2 was demonstrated by flow cytometry through staining with a 1:200 dilution of an allophycocyanin (APC)-labeled anti-CD2 antibody (RPA-2.10 clone, BioLegend) for 30 min on ice. Wildtype (untreated), CD2-KO or mock-treated primary CD4+ T cells were incubated with 10 µg/ml of the chimeric CD2 Ab or an isotype control for 60 min on Incubation:Article Title: Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors. Article Snippet: ildtype or CD2-KO CD4+ T cells was analyzed. Successful knockout of CD2 was demonstrated by flow cytometry through staining with a 1:200 dilution of an allophycocyanin (APC)-labeled anti-CD2 antibody (RPA-2.10 clone, BioLegend) for 30 min on ice. Wildtype (untreated), CD2-KO or mock-treated primary CD4+ T cells were incubated with 10 µg/ml of the chimeric CD2 Ab or an isotype control for 60 min on Binding Assay:Article Title: Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors. Article Snippet: ildtype or CD2-KO CD4+ T cells was analyzed. Successful knockout of CD2 was demonstrated by flow cytometry through staining with a 1:200 dilution of an allophycocyanin (APC)-labeled anti-CD2 antibody (RPA-2.10 clone, BioLegend) for 30 min on ice. Wildtype (untreated), CD2-KO or mock-treated primary CD4+ T cells were incubated with 10 µg/ml of the chimeric CD2 Ab or an isotype control for 60 min on Control:Article Title: Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors. Article Snippet: ildtype or CD2-KO CD4+ T cells was analyzed. Successful knockout of CD2 was demonstrated by flow cytometry through staining with a 1:200 dilution of an allophycocyanin (APC)-labeled anti-CD2 antibody (RPA-2.10 clone, BioLegend) for 30 min on ice. Wildtype (untreated), CD2-KO or mock-treated primary CD4+ T cells were incubated with 10 µg/ml of the chimeric CD2 Ab or an isotype control for 60 min on Knock-Out:Article Title: Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors. Article Snippet: ildtype or CD2-KO CD4+ T cells was analyzed. Successful knockout of CD2 was demonstrated by flow cytometry through staining with a 1:200 dilution of an allophycocyanin (APC)-labeled anti-CD2 antibody (RPA-2.10 clone, BioLegend) for 30 min on ice. Wildtype (untreated), CD2-KO or mock-treated primary CD4+ T cells were incubated with 10 µg/ml of the chimeric CD2 Ab or an isotype control for 60 min on |